Market Research Life Sciences Market Research Pharmaceuticals Market Research Clinical Trial Market Research

Alzheimer’s Disease Therapeutics (2022 Edition) – Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)

Best Price Guarantee Length Publisher Published Date SKU
from $2,400 200 Pages Azoth Analytics October, 2022 AZAN17490062
Best Price Guarantee
Price from $2,400
Length 200 Pages
Publisher Azoth Analytics
Published Date October, 2022
SKU AZAN17490062

Alzheimer’s Disease Therapeutics (2022 Edition) – Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)

Executive Summary

According to Azoth Analytics research report, the Alzheimer’s disease Therapeutics- Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.

The Alzheimer’s disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer’s disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.

Alzheimer’s prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.

Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.

Scope of the Report

  • The report analyses the Alzheimer’s Disease Therapeutics in the Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
  • The report analyses Alzheimer’s disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
  • The report analyses the Alzheimer’s disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
  • The Alzheimer’s Disease Therapeutics- Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
  • The key insights of the report have been presented through the leading company shares.
  • Also, the major trends, drivers and challenges as well as unmet needs of the industry has been analysed in the report.
  • The companies analysed in the report include Eli-Lily & Co, Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.
Key Target Audience
  • Alzheimer’s Disease Therapeutics Companies
  • End Users (Hospitals and clinics)
  • Research and Development (R&D) Organizations
  • Government Bodies & Regulating Authorities
  • Investment Banks and Equity Firms


1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Dashboard
Table 1: Alzheimer's Disease Therapeutics for next 7 years (in USD Millions)
Table 2: Alzheimer's Disease Therapeutics Size, By Product Type, 2018 & 2028 (USD Million)
Table 3: Alzheimer's Disease Therapeutics Size, By Ampere Rating, 2021 (%)
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
4.1 Global, Region-wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
5.1 Companies - Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
Table 4: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
Table 5: Eli Lilly and Company Revenue, By Business Segments, 2021 (%)
Table 6: Eli Lilly and Company Revenue, By Geographical Segments, 2021 (%)
Table A1: Key Company Financials, 2019-2021
5.2.2 Elsal Co., Ltd.
Table 7: Eisai Co., Revenues, 2019-2021 (USD Million)
Table 8: Eisai Co., Revenue, By Business Segments, 2021 (%)
Table 9: Eisai Co., Revenue, By Geographical Segments, 2021 (%)
Table A2: Key Company Financials, 2019-2021
5.2.3 BioVie
5.2.4 Johnson & Johnson
Table 10: Johnson & Johnson Revenues, 2019-2021 (USD Million)
Table 11: J&J Revenue, By Business Segments, 2021 (%)
Table 12: J&J Revenue, By Geographical Segments, 2021 (%)
Table A3: Key Company Financials, 2019-2021
5.2.5 Otsuka Pharmaceutical Co., Ltd.
Table 13: Otsuka Pharmaceuticals Revenues, 2019-2021 (USD Million)
Table 14: Otsuka Revenue, By Business Segments, 2021 (%)
Table 15: Otsuka Revenue, By Business Segments, 2020 (%)
Table A4: Key Company Financials, 2019-2021
5.2.6 H. Lundbeck A/S
Table 16: H. Lundbeck Revenues, 2019-2021 (USD Million)
Table 17: H. Lundbeck Revenue, By Business Segment by Product, 2021 (%)
Table 18: H. Lundbeck Revenue, By Geographical Segments, 2021 (%)
Table A5: Key Company Financials, 2019-2021
5.2.7 Novartis
Table 19: Novartis Revenues, 2019-2021 (USD million)
Table 20: Novartis Revenue, By Business Segments, 2021 (%)
Table 21: Novartis Revenue, By Geographic Segments, 2021 (%)
Table A6: Key Company Financials, 2019-2021
5.2.8 Cognition Therapeutics
5.2.9 Merck Sharp & Dohme LLC
Table 22: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
Table 23: Merck & Co., Inc. Revenue, By Business Segments, 2021 (%)
Table 24: Merck & Co., Inc. Revenue, By Geographic segment, 2021 (%)
Table A7: Key Company Financials, 2019-2021
5.2.10 Biogen
Table 25: Biogen Revenues, 2019-2021 (USD Million)
Table 26: Biogen Revenue, By Business Segments- By Products, 2021 (%)
Table 27: Biogen Revenue, By Geographic Segments, 2021 (%)
Table A8: Key Company Financials, 2019-2021
6. Alzheimer's Disease Background
6.1 AD Fact Sheet
6.2 Epidemiology
Table 28: Global Prevalence of Alzheimer's disease and other dementias, 2017-2019 (Millions)
Table 29: Global Incidence of Alzheimer's disease and other dementias, 2017-2019 (Millions)
Table 30: Global Prevalence of Alzheimer's disease and other dementias, In Females, 2017-2019 (Millions)
Table 31: Global Prevalence of Alzheimer's disease and other dementias, In Males, 2017-2019 (Millions)
6.3 Causes and Risk Factors
Table 32: Global Diabetes data report 2000 ó 2045(E), (in thousands)
Table 33: Estimated global prevalence and numbers of people with obesity and severe obesity in 2020, 2025 (E) and 2030 (E)
Table 34: Estimated prevalence of obesity amongst women in, 2030 (E)
Table 35: Estimated prevalence of obesity amongst men in, 2030 (E)
6.4 Diagnosis and Assessment
6.5 Unmet Needs
7. Therapeutics in Pipeline
Table A9: Total Drugs in Alzheimerís Disease Pipeline
7.1 Pipeline Scenario
7.2 Alzheimerís Therapeutics Comparative Review
8. Pipeline Analysis
9. Phase I Therapeutics Overview
Table A10: Total Alzheimer's Disease Drugs in Phase I of Pipeline
Fig.36: Therapeutics in Phase I, by Molecule type
9.1 LY3372993
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.2.2 Drug Description
9.2.3 Outcomes
9.3 anle138b
9.3.1 Drug Description
9.3.2 Outcomes
9.3.3 Collaborators
9.4 ASN51
9.4.1 Drug Description
9.4.2 Outcomes
9.4.3 Collaborators
9.5 CMS121
9.5.1 Drug Description
9.5.2 Outcomes
9.5.3 Collaborators
9.6 IBC-Ab002
9.6.1 Drug Description
9.6.2 Outcomes
9.6.3 Collaborators
9.7 LX1001
9.7.1 Drug Description
9.7.2 Outcomes
9.8 MK-2214
9.8.1 Drug Description
9.8.2 Outcomes
9.9 MK-8189
9.9.1 Drug Description
9.9.2 Outcomes
9.10 ACU193
9.10.1 Drug Description
9.10.2 Outcomes
9.10.3 Collaborators
9.11 NIO752
9.11.1 Drug Description
9.11.2 Outcomes
9.12 ALN-APP
9.12.1 Drug Description
9.12.2 Outcomes
9.13 TB006
9.13.1 Drug Description
9.13.2 Outcomes
9.14 SNK01
9.14.1 Drug Description
9.14.2 Outcomes
9.15 Pepinemab
9.15.1 Drug Description
9.15.2 Outcomes
9.15.3 Collaborators
9.16 GB-5001
9.16.1 Drug Description
9.16.2 Outcomes
9.17 AC-1202
9.17.1 Drug Description
9.17.2 Outcomes
9.18 SHR-1707
9.18.1 Drug Description
9.18.2 Outcomes
9.19 BEY2153
9.19.1 Drug Description
9.19.2 Outcomes
9.20 JNJ-40346527
9.20.1 Drug Description
9.20.2 Outcomes
9.20.3 Collaborators
9.21 APNmAb005
9.21.1 Drug Description
9.21.22 Outcomes
9.22 NPT 2042
9.22.1 Drug Description
9.22.2 Outcomes
9.23 ALZ-101
9.23.1 Drug Description
9.23.2 Outcomes
10. Phase I/II Therapeutics Overview
Table A11: Total Alzheimerís Disease Drugs in Phase I/II of Pipeline
Fig.37: Therapeutics in Phase I/II by Molecule type
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProô/ PrimeMSKô
10.2.1 Drug Description
10.2.2 Outcomes
10.2.3 Collaborators
10.3 TB006
10.3.1 Drug Description
10.3.2 Outcomes
10.4 RO7126209
10.4.1 Drug Description
10.4.2 Outcomes
10.5 DNL593
10.5.1 Drug Description
10.5.2 Outcomes
10.5.3 Collaborators
10.6 BIIB080
10.6.1 Drug Description
10.6.1 Outcomes
10.7 E2814
10.7.1 Drug Description
10.7.2 Outcomes
10.8 Tdap
10.8.1 Drug Description
10.8.2 Outcomes
10.8.3 Collaborators
10.9 ACI-35.030/ JACI-35.054
10.9.1 Drug Description
10.9.2 Outcomes
10.9.3 Collaborators
10.10 ACI-24.060
10.10.1 Drug Description
10.10.2 Outcomes
10.10.3 Collaborators
10.11 IVL3003
10.10.1 Drug Description
10.10.2 Outcomes
11. Phase II Therapeutics Overview
Table A12: Total Alzheimerís Disease Drugs in Phase II of Pipeline
Table 38: Therapeutics in Phase II by Molecule type
11.1 Lecanemab
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.2 Lomecel-B
11.2.1 Drug Description
11.2.2 Outcomes
11.2.3 Collaborators
11.3 AL002
11.3.1 Drug Description
11.3.2 Outcomes
11.3.3 Collaborators
11.4 AL001
11.4.1 Drug Description
11.4.2 Outcomes
11.5 CT1812 (Elaya)
11.5.1 Drug Description
11.5.2 Outcomes
11.6 APH-1105
11.6.1 Drug Description
11.6.2 Outcomes
11.7 ATH-1017
11.7.1 Drug Description
11.7.2 Outcomes
11.8 T-817MA
11.8.1 Drug Description
11.8.2 Outcomes
11.9 Montelukast buccal film
11.9.1 Drug Description
11.9.2 Outcomes
11.10 ABBV-916
11.10.1 Drug Description
11.10.2 Outcomes
11.11 Bepranemab
11.11.1 Drug Description
11.11.2 Outcomes
11.12 TB006
11.12.1 Drug Description
11.12.2 Outcomes
11.13 LY3372689
11.13.1 Drug Description
11.13.2 Outcomes
11.14 MW150
11.14.1 Drug Description
11.14.2 Outcomes
11.14.3 Collaborators
11.15 EX039
11.15.1 Drug Description
11.15.2 Outcomes
11.15.3 Collaborators
11.16 JNJ-42847922
11.16.1 Drug Description
11.16.2 Outcomes
11.17 REM0046127
11.17.1 Drug Description
11.17.2 Outcomes
11.18 Bryostatin 1
11.18.1 Drug Description
11.18.2 Outcomes
11.18.3 Collaborators
11.19 NanoLithiumÆ NP03
11.19.1 Drug Description
11.19.2 Outcomes
11.20 AstroStem
11.20.1 Drug Description
11.20.2 Outcomes
11.21 Gantenerumab
11.21.1 Drug Description
11.21.2 Outcomes
11.22 Semorinemab
11.22.1 Drug Description
11.22.1 Outcomes
11.23 Obicetrapib
11.23.1 Drug Description
11.23.2 Outcomes
11.24 ALZ-801
11.24.1 Drug Description
11.24.2 Outcomes
11.25 CY6463
11.25.1 Drug Description
11.25.2 Outcomes
11.26 Crenezumab
11.26.1 Drug Description
11.26.2 Outcomes
11.26.3 Collaborators
11.27 T3D-959
11.27.1 Drug Description
11.27.2 Outcomes
11.28 PMZ-1620
11.28.1 Drug Description
11.28.2 Outcomes
11.29 GV1001
11.29.1 Drug Description
11.29.2 Outcomes
11.30 ACZ885
11.30.1 Drug Description
11.30.2 Outcomes
11.31 PQ912
11.31.1 Drug Description
11.31.2 Outcomes
11.31.3 Collaborators
11.32 APH-1105
11.32.1 Drug Description
11.32.2 Outcomes
11.33 SLS-005
11.33.1 Drug Description
11.33.2 Outcomes
11.33.3 Collaborators
11.34 Flos gossypii flavonoids
11.34.1 Drug Description
11.34.2 Outcomes
11.34.3 Collaborators
11.35 Human Mesenchymal Stem cells (MSCs),
11.35.1 Drug Description
11.35.2 Outcomes
11.36 JNJ-63733657
11.36.1 Drug Description
11.36.2 Outcomes
11.37 IGC-AD1
11.37.1 Drug Description
11.37.2 Outcomes
11.38 TW001
11.38.1 Drug Description
11.38.2 Outcomes
11.39 ABvac40
11.39.1 Drug Description
11.39.2 Outcomes
12. Phase II/III Therapeutics Overview
Table A13: Total Alzheimerís Disease Drugs in Phase II/III of Pipeline
Fig.39: Therapeutics in Phase II/III by Molecule type
12.1 Tricaprilin
12.1.1 Drug Description
12.1.2 Outcomes
12.2 ANAVEX2-73
12.2.1 Drug Description
12.2.3 Outcomes
12.3 Piromelatine
12.3.1 Drug Description
12.3.2 Outcomes
12.3.3 Collaborators
12.4 AGB101
12.4.1 Drug Description
12.4.2 Outcomes
12.4.3 Collaborators
13. Phase III Therapeutics Overview
Table A14: Total Alzheimer's Disease Drugs in Phase III of Pipeline
Table 40: Therapeutics in Phase III by Molecule type
13.1 Simufilam
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.2.1 Drug Description
13.2.2 Outcomes
13.3 Lecanemab
13.3.1 Drug Description
13.3.2 Outcomes
13.3.3 Collaborators
13.4 Nilotinib BE
13.4.1 Drug Description
13.4.2 Outcomes
13.4.3 Collaborators
13.5 Brexpiprazole
13.5.1 Drug Description
13.5.2 Outcomes
13.5.3 Collaborators
13.6 Masitinib
13.6.1 Drug Description
13.6.2 Outcomes
13.7 Remternetug
13.7.1 Drug Description
13.7.2 Outcomes
13.8 Donanemab
13.8.1 Drug Description
13.8.2 Outcomes
13.9 NE3107
13.9.1 Drug Description
13.9.2 Outcomes
13.10 Gantenerumab
13.10.1 Drug Description
13.10.2 Outcomes
13.11 GV-971
13.11.1 Drug Description
13.11.2 Outcomes
13.12 Aducanumab
13.12.1 Drug Description
13.12.2 Outcomes
13.13 TRx0237
13.13.1 Drug Description
13.13.2 Outcomes
13.14 Semagludtide
13.14.1 Drug Description
13.14.2 Outcomes
13.15 BPDO-1603
13.15.1 Drug Description
13.15.2 Outcomes
13.16 AR1001
13.16.1 Drug Description
13.16.2 Outcomes
13.17 KarXT
13.17.1 Drug Description
13.17.2 Outcomes
13.18 AXS-05
13.18.1 Drug Description
13.18.2 Outcomes
14. Phase IV Therapeutics Overview
Table A15: Total Alzheimer's Disease Drugs in Phase IV of Pipeline
Table 41: Therapeutics in Phase IV by Molecule type
14.1 Choline Alfoscerate
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.2.1 Drug Description
14.2.2 Outcomes
14.3 Rivastigmine
14.3.1 Drug Description
14.3.2 Outcomes
14.4 GV-971
14.4.1 Drug Description
14.4.2 Outcomes
15. Preclinical Phase therapeutics Overview
Table A16: Total Alzheimer's Disease Drugs in Preclinal Phase of Pipeline
Table 42: Therapeutics in Preclinical Phase, by Molecule type
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123
15.2.1 Drug Description
15.2.2 Outcomes
16. Pipeline analysis, By molecule type
16.1 Alzheimerís Therapeutics Comparative Review, by Molecule type
17. Pipeline analysis, By Route of Administration
17.1 Alzheimerís Therapeutics Comparative Review, By Route of Administration

$2,400
$3,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings